Cadrenal Therapeutics, Inc. 8-K

What Happened Cadrenal Therapeutics, Inc. (CVKD) filed a Form 8-K reporting that its Chief Medical Officer, Dr. James J. Ferguson III, informed the Board on July 7, 2026 that he will resign his position effective July 31, 2026. The company is conducting a search for a replacement and the parties are negotiating a separation agreement and release to be executed in the future. The 8-K reporting this change was filed on July 10, 2026 under Item 5.02.

Key Details

• Dr. James J. Ferguson III notified the Board on July 7, 2026 of his decision to resign.
• Resignation effective date (Separation Date): July 31, 2026.
• Cadrenal is actively searching for a successor and is negotiating a separation agreement and release with Dr. Ferguson.
• Change reported on Form 8-K (Item 5.02) filed July 10, 2026.

Why It Matters A CMO departure is material for a clinical-stage biotech because it can affect clinical program leadership, regulatory interactions, and investor confidence in program continuity. Investors should watch for updates on interim clinical leadership, the terms of the separation agreement, and announcements about a permanent replacement, which the company has said it is seeking. Future filings and press releases may provide information on any impact to timelines or ongoing studies.